Nephros Inc. said it has signed an agreement to enable a Vanderbilt Dialysis Clinic to offer hemodiafiltration (HDF) to patients. The agreement provides Vanderbilt with the Company’s OLpür H2H Hemodiafiltration System, dialysis supplies and service support to facilitate HDF treatment. The system is the only FDA 510(k) cleared medical device that enables nephrologists to provide HDF treatment to patients with ESRD.
Vanderbilt will be able to begin transferring selected and qualified patients over to HDF therapy in the next few months, Nephros said. These efforts will be lead by Dr. Jamie P. Dwyer, Associate Professor of Medicine in the Nephrology and Hypertension Division at Vanderbilt University School of Medicine and Co-Director of the Vanderbilt Nephrology Trials Center. Dr. Dwyer currently serves as Medical Director of the Vanderbilt Dialysis Clinic chosen to offer HDF treatment.